**TABLE F10.- allergy challenges and functional outcomes: pft SCIT vs SLIT**

| **Study** | **Allergen** | **Arms** | **Time of measure** | **Scale description** | **SCORE** | **Value Pre** | **Value post** | **Comparative values** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Tahamiler 20063 | Dust mite | SLITSCIT | 6 years | Nasal provocation challengeModified Gerth van Wijk and Dieges method | 0-9 | 5.5±1.45.6±1.5 | 2.8±2.01.4±1.2 | SLIT pre vs post, p<0.05SCIT pre vs post, p<0.05 |
| Eifan 20105 | Dust mite | SLITSCITPharmacotherapy | 1 year | Titrated allergen specific nasal provocation test |  | NRNRNR | NRNRNR | Significant increase in nasal provocative dose in SLIT (p=0.01) and SCIT (p=0.005) when compared to pharmacotherapy group at the end of 12 months. No significant differences between SLIT and SCIT were observed. |
| Mungan19996 | Dust mites | SLITSCITPlacebo | 1 year | Methacholine bronchial provocation test |  | NRNRNR | NRNRNR | SLIT pre vs post p=NSSCIT pre vs post p=NSPlacebo pre vs post p=NS |
| Yukselen20117 | Dust mites | SCITSLITPlacebo | 1 year | HDM-Specific Nasal provocation | NR | NR | NR | SCIT pre vs post, p=0.05SLIT pre vs post, p=0.01SCIT vs SLIT p= 0.31 |
| Yukselen20117 | Dust mites | SCITSLITPlacebo | 1 year | HDM-Specific Bronchial provocation | NR | NR | NR | SCIT pre vs post, p=0.03SLIT pre vs post, p=0.56Placebo pre vs post, p=0.78SCIT vs SLIT p= 0.91 |
| Keles20118 | Dust mites | SCITSLITSCIT+SLITPharmacotherapy | 1 year | Allergen specific nasal provocation dose | NR | 4.9557 | 344.47.5 | SCIT vs Pharmacotherapy p=0.005SLIT vs Pharmacotherapy p=0.044SCIT+SLIT vs Pharmacotherapy p=0.035 |
| Keles20118 | Dust mites | SCITSLITSCIT+SLITPharmacotherapy | 1 year | Methacholine PC20 | NR | NR | NR | No significant change was detected in any of the groups |

PFT: Pulmonary Function Test NS: Not significant PEF: Peak Expiratory Flow FEV: forced expiratory volume